Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060.

Published byLilian Reed Modified over 8 years ago

Similar presentations

Presentation on theme: "Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060."— Presentation transcript:

1 Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

2 Serum Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

3 Plaque Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

4 Percentage of plaques with minor or heavy staining for CD68 positive cells Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

5 Patients treated with high statin dose showed a significant decrease in MMP-8 activity, whereas a tendency is observed for MMP-9 Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

6 MMP-8 and -9 levels of atherosclerotic plaques with moderate/heavy (+) staining for CD68 positive cells compared with plaques with no/minor (-) staining and different groups of statin treatment Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

7 MMP-8 and -9 levels in a selected group of patients Selection was based on CD68 plaque staining and atorvastatin treatment Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060

Download ppt "Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060."

Similar presentations

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.

OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18.

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:1851-1857.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
OUTCOME MEASURES IN PsA: IMMUNOHISTOLOGY Oliver FitzGerald.

OUTCOME MEASURES IN PsA: IMMUNOHISTOLOGY Oliver FitzGerald.
Atherosclerotic lesion area within the aortic sinus of apoE - / - and apoE - / - - hCRP + mice Gideon M. Hirschfield et al. PNAS 2005;102:8309– 8314.

Atherosclerotic lesion area within the aortic sinus of apoE - / - and apoE - / - - hCRP + mice Gideon M. Hirschfield et al. PNAS 2005;102:8309– 8314.
Westerweel PE et al. Eur Heart J 2008;29:

Westerweel PE et al. Eur Heart J 2008;29:
Baseline Characteristics of the Patients Part I

Baseline Characteristics of the Patients Part I
Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:
Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.
TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.
Section 7: Aggressive vs moderate approach to lipid lowering

Section 7: Aggressive vs moderate approach to lipid lowering
Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen 

Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen 

Similar presentations

Ads by Google